Takeda Pharmaceutical Company Limited (TAK) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

61/100

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

73

Undervalued

Momentum

42

Neutral

Sentiment

59

Mixed

Risk resilience

77

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Headquarters: JP

Market position

Day range

Current $18.18

$18.08$18.19

52-week range

Current $18.18

$12.99$18.90

Open: $18.09
Previous close: $18.13
Volume: 1.39M
Market cap: 57.85B USD
50-day average: $16.7788; +8.35% above average
200-day average: $16.5445; +9.89% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 13.56T JPY
P/E (TTM): 50.75×
P/B (TTM): 1.2×
P/S (TTM): 2×
EV / EBITDA: 9.56×
Earnings yield: 2.20%
Free cash flow yield: 6.77%
Dividend yield: 3.45%

Profitability & efficiency

Gross margin: 62.15%
Operating margin: 10.52%
Net margin: 3.91%
Return on equity: 2.60%
Return on assets: 1.31%
Return on invested capital: 3.11%

Financial health

Debt / equity: 0.65×
Current ratio: 1.27×
Altman Z-score: 1.19
Piotroski F-score: 5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

4.78T JPY+4.28%

Operating income

573.04B JPY+67.27%

Net income

203.33B JPY+88.39%

Metric (JPY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	4.78T JPY	4.58T JPY	4.26T JPY	4.03T JPY	3.57T JPY
Cost of goods sold	2.34T JPY	1.58T JPY	1.43T JPY	1.24T JPY	1.11T JPY
Gross profit	2.44T JPY	3T JPY	2.83T JPY	2.78T JPY	2.46T JPY
Research and development	716.69B JPY	730.23B JPY	729.92B JPY	633.33B JPY	526.09B JPY
Selling, general, and administrative	1.15T JPY	1.1T JPY	1.05T JPY	997.31B JPY	886.36B JPY
Operating expenses	1.87T JPY	2.66T JPY	2.62T JPY	2.29T JPY	2T JPY
Interest income	223.91B JPY	19.64B JPY	78.1M JPY	5.51B JPY	4.59B JPY
Interest expense	379.14B JPY	137.31B JPY	1.06B JPY	116.97B JPY	122.43B JPY
Depreciation and amortization	764.62B JPY	761.4B JPY	644.46B JPY	664.4B JPY	583.15B JPY
Operating income	573.04B JPY	342.59B JPY	214.08B JPY	490.51B JPY	460.84B JPY
Net income	203.33B JPY	107.93B JPY	144.07B JPY	317.02B JPY	230.06B JPY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate: 27%; 3 beats, 8 misses, 0 met estimates
Average EPS surprise: -75.71%; 11 comparable reports
Latest EPS result: 0.23; Estimate 0.17 · Beat by 33.21%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Latest fiscal-year EPS: 63.91; FY2025 · +90.10% year over year
Latest fiscal-year revenue: 4.78T JPY; FY2025 · +4.28% year over year
Next fiscal-year EPS consensus: 61.33; FY2027 · 2 analysts
Next fiscal-year revenue consensus: 4.62T JPY; FY2026 · 8 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

6 ratings

Strong buy00%

Buy583%

Hold117%

Sell00%

Strong sell00%

TAK news

businesswire.comAug 24, 2026

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of…

Read source

zacks.comAug 18, 2026

Wall Street Analysts Think Takeda Pharmaceutical Co. (TAK) Could Surge 26.41%: Read This Before Placing a Bet

The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…

Read source

zacks.comAug 17, 2026

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and…

Read source

zacks.comAug 17, 2026

Best Income Stocks to Buy for August 17th

SBLK, TAK and STBA made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 17, 2026.

Read source

zacks.comAug 17, 2026

New Strong Buy Stocks for August 17th

TAK, VLO, PFX, SBLK and RELY have been added to the Zacks Rank #1 (Strong Buy) List on August 17, 2026.

Read source

seekingalpha.comAug 7, 2026

Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concern

Takeda Pharmaceuticals (TAK) remains a hold, with shares near 52-week highs and uncertainty about a major successor to Entyvio. TAK's Q1 showed 10% revenue growth, but bottom-line weakness from higher taxes and lower…

Read source

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.5981

2025 complete year-25.6% since 2021

2026 partial: $0.3083

$0.8035

2,021

$0.6596

2,022

$0.629

2,023

$0.6183

2,024

$0.5981

2,025

$0.3083

2,026*

* Partial calendar year in the available dividend history.

Corporate action history

Action	Ex-dividend date	Details	Record date	Payment date
Dividend	Mar 31, 2026	$0.3083Semi-Annual	Mar 31, 2026	Jul 6, 2026
Dividend	Sep 30, 2025	$0.3221Semi-Annual	Sep 30, 2025	Dec 11, 2025
Dividend	Mar 31, 2025	$0.276Semi-Annual	Mar 31, 2025	Jul 7, 2025
Dividend	Sep 30, 2024	$0.3261Semi-Annual	Sep 30, 2024	Dec 12, 2024
Dividend	Mar 27, 2024	$0.2922Semi-Annual	Mar 28, 2024	Jul 8, 2024
Dividend	Sep 28, 2023	$0.3191Semi-Annual	Sep 29, 2023	Dec 11, 2023